Antiretroviral treatment update from the 17th international AIDS conference

AIDS Reader

Volumn 18, Issue 11, 2008, Pages 569-579

  Boyle, Brian ^a   Cohen, Cal ^b,c   Dejesus, Edwin ^d   Elion, Richard ^e   Frank, Ian ^f,g   Moyle, Graeme ^h   Sax, Paul ^g,i  

^a ViralEd LLC   (United States)

^b Community Research Initiative of England ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ORLANDO REGIONAL MEDICAL CENTER   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f Department of Medicine ^*

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^h CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; Conferences; HIV AIDS; International AIDS conference

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; IDX899; LAMIVUDINE; MARAVIROC; PLACEBO; RALTEGRAVIR; RDEA806; RILPIVIRINE; UNCLASSIFIED DRUG; ZIDOVUDINE; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BEHAVIOR MODIFICATION; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE TRANSMISSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; GLOMERULUS FILTRATION RATE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MEDICAL EDUCATION; QT PROLONGATION; REVIEW; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; UNPLEASANT DREAM; VACCINATION; VIRUS LOAD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CONFERENCE PAPER; DRUG ANTAGONISM;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; CYCLOHEXANES; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; PYRROLIDINONES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLES;

EID: 58149201238     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Cohen M. Prevention of the sexual transmission of HIV-1: a view from early in the 21st century. 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract TUPL0101.
2. Montaner J, Kerr T, Li K, et al. Longitudinal community plasma HIV RNA level and HIV incidence among injection drug users. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract LBPE1160.
3. Sax P, Tierney C, Collier A, et al. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naive persons with screening HIV RNA;≥ 100,000 c/mL. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract THAB0303.
4. Pappa K, Hernandez J, Ha B, et al. Abacavir/lamivudine (ABC/3TC) shows robust virologic responses in ART-naive patients for baseline (BL) viral loads (VL) of 2 100,000 c/mL and < 100,000 c/mL by endpoint used in ACTG5202.17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract THAB0304.
5. Smith K, Fine D, Patel P, et al. Similarity in efficacy and stifety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAT Study. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract LBPE1138.
6. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration [published correction appears in Lancet. 2008;372:292]. Lancet. 2008;371:1417-1426.
7. Lundgren J, Neuhaus J, Babiker A, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract THAB0305.
8. Cutrell A, Hernandez J, Yeo J, et al. Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction (MI)? No association identified in pooled summary of 54 clinical trials. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract WEAB0106.
9. Gallant J, Pozniak A, Dejesus E, et al. Renal safety profile of tenofovir DF (TDF) - containing vs thymidine analog containing regimens through 144 weeks in antiretroviral-naive patients. 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract THPE0186.
10. 10.Madruga J,Cassetti I, Suleiman J, et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV - 1-infected patients: a four-year follow-up. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract TUPE0054.
11. Casetti I, Ms druga I, Etzel A, et al. The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naíve patients through seven years. 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract TUPE0057.
12. Castellano C, Williams W, Kepler T, et al. Clinical predictors of tenofovir associated nephrotoxicity in HIV-l-infected patients. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract WEAB104.
13. Rawlings K, Klein 1, Klingler E, et al. Impact of drug therapy and comorbidities on the development of renal impairment in HIV-infected patients: results of a large retrospective database study. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract THPE0182.
14. Short W, Solari P, Kaplan B. Comparison of renal function in a cohort of patients on tenofovir (TDF) versus non-tenofovir containing regimens. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract THPE0202.
15. Towner W, Haigney Z, Sension M, et al. Efficacy, safety and tolerability of etravirine with and without darunavir and/or raltegravir in treatment experienced patients: preliminary analysis of TMC125-C214 Early Access Programme (EAP). 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract TUPE0066.
16. Markowitz M, Nguyen B, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract TUAB0102.
17. Markowitz M, Nguyen BY, Gotuzzo E, et al; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. JAcquir Immune Defic Syndr. 2007;46:125-133.
18. albot A, Machouf N, Thomas R, et al. Retrospective analysis of a switch from nfuvirtide to raltegravir in patients with undetectable viral load: efficacy and afety at 12 weeks in a Montreal cohort. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract TUPE0112.
19. Howner W, Klein D, Follansbee S, et al. Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on an enfuvirtide based regimen. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract TUPE0115.
20. Khanlou H, Allavena C, Billaud E, et al. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir. 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract TUPE0087.
21. Nelson M, I-isher M, Gonzalez-Garcia J, et al. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc (MVC) plus an optimized background therapy (OBT) versus placebo (PBO) plus OBT in the MOTIVATE 1 and 2 trials. 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract TUPE0119.
22. McFadyen L, Jacqmin P, Wade J, Weatherley B. Maraviroc exposure-efficacy (< 50 copies/mL) analysis in HIV-l-infected treatment-naive subjects-ITT population (MERIT study). 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract TUPE0053.
23. Steigbigel RT, Cooper DA, Kumar PN, et al; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
24. Yazdanpariah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS139 TRIO trial 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract THAB0406.
25. DeJesus E; ACH443-015 Study Team. Elvucitabine phase II24 week interim results show safety and efficacy profiles similar to lamivudine in naive HIV-1 in fected patients 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract TUPE0010.
26. Cox S, Moore S, Southby J, Alsumde A. Safety profile of apricitabine, a novel NRTI, during 24-week dosing in experienced HIV-1 infected patients. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract TUAB0106.
27. Santoscoy M, Cahn P, Gonsalez C, et al. TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204.17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract TUAB0103.
28. Moyle G, Boffito M, Manhard K, et al. Antiviral activity of RDEA806, a novel HIV non-nuckoside reverse transcriptase inhibitor, in treatment of naive HIV patients. 17th International AIDS Conference; August 3-8,2008; Mexico City. Abstract THAB0403.
29. Zala C, Murphy R, Zhou X, et al. IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naíve HIV-l-infected subjects. 17th International AIDS Conference; August 3-8, 2008; Mexico City. Abstract THAB0402.